Condition
Follicular B-cell Non-Hodgkin's Lymphoma
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
75.0%
3 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Terminated3
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07713459Phase 2Not Yet Recruiting
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
NCT05645744Terminated
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
NCT05360238Phase 1TerminatedPrimary
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
NCT02594163Phase 2Terminated
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Showing all 4 trials